期刊文献+

慢性肾脏病骨矿盐代谢及骨密度检测分析 被引量:1

The analysis of bone mineral salt metabolism and bone density detection on chronic kidney disease
原文传递
导出
摘要 目的 探讨慢性肾脏病(CKD)不同病期患者的骨密度及骨矿盐代谢指标的变化情况.方法 非透析CKD患者345例,根据2002年美国肾脏病基金会(NKF)K/DOQI专家组CKD分期以及我国慢性肾衰竭分期方法按血清肌酐(SCr)、肾小球滤过率(GFR)水平分为CKD 1 ~5期,CKD 1期75例,CKD 2期65例,CKD 3期65例,CKD4期65例,CKD 5期75例,抽取受试者静脉血,分离血清,用离子选择电极法测定血钙、磷和SCr;用苦味酸法测定血尿素氮(BUN);用化学发光法测定血全段甲状旁腺激素(iPTH)及1,25羟基维生素D3[1,25(OH)2 VitD3].结果 CKD患者随着肾功能下降,血iPTH、磷水平逐渐升高,以CKD4期和CKD 5期升高明显,与CKD1期比较差异有统计学意义[(289.6578±187.7945)、(482.0667±232.2065)μg/L比(77.8431±52.9760) μg/L,(1.6938±0.1960)、(2.6034±0.5986) mmol/L比(1.3833±0.4068) mmol/L,P< 0.05];血钙、1,25(OH)2VitD3水平逐渐下降,以CKD 4期和CKD5期下降明显,与CKD 1期比较差异有统计学意义[(1.9185±0.4633)、(1.8293±0.3075) mmol/L比(2.0893±0.2245) mmol/L,(10.0892±0.2638)、(7.6058±0.4356) ng/L比(18.0036±0.3218) ng/L,P< 0.05].随着肾功能减退,骨质疏松的比例也逐渐升高,且以CKD5期最显著,与CKD 1期和CKD 2期比较差异有统计学意义[60.00%(45/75)比20.00%(15/75)、23.08%(15/65),P<0.05].结论 随着肾功能减退,血iPT-H、磷水平逐渐升高,血钙、1,25 (OH)2 VitD3水平以及骨密度逐渐下降,尤其以CKD4期和CKD5期最明显. Objective To discuss the relationship between bone mineral salt metabolism index change and bone density in different stage of chronic kidney disease (CKD).Methods Three hundred and forty-five non-dialysis patients with CKD were enrolled in this study.According to the serum creatinine (SCr),glomerular filtration rate (GFR),they were divided into stage 1-5.CKD 1 had 75 cases,CKD 2 had 65 cases,CKD 3 had 65 cases,CKD 4 had 65 casès,CKD 5 had 75 cases.The level of blood calcium (Ca),phosphorus (P) and SCr were detected by ion selective electrode method.The level of urea nitrogen (BUN) was detected by picric acid method.The level of intact parathyroid hormone (iPTH) and 1,25 (OH)2VitD3 were detected by chemiluminescence.Results With the decline of renal function,the level of iPTH and blood P increased gradually,especially in stage CKD 4 and CKD 5,and compared with stage CKD 1,there were significantly differences [(289.6578 ± 187.7945),(482.0667 ± 232.2065) μ g/L vs.(77.8431 ± 52.9760) μ g/L and (1.6938 ± 0.1960),(2.6034 ± 0.5986) mmol/L vs.(1.3833 ± 0.4068) mmol/L,P 〈 0.05].The level of blood Ca and 1,25 (OH)2VitD3 decreased gradually,especially in stage CKD 4 and CKD 5,and compared with stage CKD 1,there were significantly differences [(1.9185 ±0.4633),(1.8293 ± 0.3075) mmol/L vs.(2.0893 ± 0.2245) mmoi/L and (10.0892 ± 0.2638),(7.6058 ±0.4356) ng/L vs.(18.0036 ± 0.3218) ng/L,P 〈 0.05].With the decline of renal function,the proportion of osteoporosis also gradually increased,especially in stage CKDS,and compared with stage CKD 1 and CKD 2,there was significantly difference [60.00% (45/75) vs.20.00% (15/75),23.08% (15/65),P 〈 0.05].Conclusion With the decline of renal function,the level of blood P and iPTH increase,and blood Ca,1,25(OH)2VitD3,bone density decrease,especially in stage CKD 4 and CKD 5 patients.
出处 《中国医师进修杂志》 2013年第18期4-6,共3页 Chinese Journal of Postgraduates of Medicine
关键词 肾功能不全 慢性 骨矿盐代谢 骨密度 Kidney failure, chronic Bone mineral salt metabolism Bone density
  • 相关文献

参考文献10

二级参考文献39

共引文献60

同被引文献18

  • 1National Kidney Foundation. K/DOQI clinical practice guidelines forbone metabolism and disease in chronic kidney disease [ J ] . Am JKidney Dis, 2003 ,42( Suppl 3) :S1 -S201.
  • 2Lewiecki EM , Watts NB. New guidelines for the prevention and treat-ment of osteoporosis [ J ]. South Med J ,2009 ,102 : 175 - 179.
  • 3Yenchek RH,Ix JH , Shlipak MG, et al. Bone mineral density andfracture risk in older individuals with CKD[ J] . Clin J Am Soc Neph-rol ,2012 ,7 (7) :1130 -1136.
  • 4Iimori S, Mori Y , Akita W, et al. Diagnostic usefulness of bone miner-al density and biochemical markers of bone turnover in predicting frac-ture in CKD stage 5 D patients—a single - center cohort study [ J ].Nephrol Dial Transplant, 2012 ,27 ( 1) :345 - 351.
  • 5Akaberi S , Simonsen 0,Lindergard B , et al. Can DXA predict frac-tures in renal transplant patients? [J]. Am J Transplant, 2008,8(12) : 2647 -2651.
  • 6Jamal SA, Bauer DC , Ensrud KE, et al. Alendronate treatment in-women with normal to severely impaired renal function : ananalysis ofthe fracture intervention trial [ J ]. J Bone Miner Res, 2007 , 22 ( 4 ):503 -508.
  • 7Miller PD, Roux C , Boonen S, et al. Safety and efficacy of risedr-onate in patients with age - relatedreduced renal function as estimatedby the Cockcroft and Gaultmethod : a pooled analysis of nine clinicaltrials[J]. J Bone Miner Res,2005 ,20( 12) :2105 -2115.
  • 8Ishani A,Blackwell T, Jamal SA,et al. The effect of raloxifene treat-ment in postmenopausal women with CKD [ J ]. J Am Soc Nephrol,2008,19(7) :1430 - 1438.
  • 9Miller PD , Schwartz EN , Chen P, et al. Teriparatide in postmenopa-usal women with osteoporosis and mild ormoderate renal impairment[J] . Osteoporos Int ,2007 ,18( 1 ) :59 - 68.
  • 10Jamal SA, Ljunggren 0,Stehman - Breen C,et al. Effects of deno-sumab onfracture and bonemineral density by level of kidney function[J]. J Bone Miner Res ,2011 ,26 ( 8) :1829 - 1835.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部